```

[Federal Register Volume 86, Number 122 (Tuesday, June 29, 2021)]
[Notices]
[Pages 34242-34243]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-13851]

=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Advisory Council on Alzheimer's Research, Care, and Services; 
Meeting

AGENCY: Assistant Secretary for Planning and Evaluation, HHS.

ACTION: Notice of meeting.

-----------------------------------------------------------------------

SUMMARY: This notice announces the public meeting of the Advisory 
Council on Alzheimer's Research, Care, and Services (Advisory Council). 
The Advisory Council provides advice on how to prevent or reduce the 
burden of Alzheimer's disease and related dementias on people with the 
disease and their caregivers. During the July 19, 2021 meeting the 
Advisory Council will discuss the implications of and opportunities 
presented by the approval of aducanumab. The Council will also hear 
updates from federal workgroups on efforts undertaken in the last 
quarter. The risk reduction subcommittee will present a summary of 
their work and recommendations. The research, clinical care, and long-
term services and supports subcommittees will present recommendations 
and the Council will vote on adopting them.

DATES: The meeting will be held on July 19, 2021 from 12:30 p.m. to 
4:30 p.m. EST.

ADDRESSES: The meeting will be virtual, streaming live at www.hhs.gov/live.
    Comments: Time is allocated on the agenda to hear public comments 
from 4:00 p.m. to 4:30 p.m. The time for oral comments will be limited 
to two (2) minutes per individual. In order to provide a public 
comment, please register by emailing your name to [email protected] by 
Thursday, July 15. On Friday, July 16, registered commenters will 
receive both a dial-in number and a link to join the meeting virtually; 
individuals will have the choice to either join virtually via the link, 
or to call in only by using the dial-in number. Note: There may be a 
30-45 second delay in the livestream video presentation of the 
conference. For this reason, if you have pre-registered to submit a 
public comment, it is important to connect to the meeting by 3:45 p.m. 
to ensure that you do not miss your name and allotted time when called. 
If you miss your name and allotted time to speak, you may not be able 
to make your public comment. All participant audio lines will be muted 
for the duration of the meeting and only unmuted by the Host at the 
time of the participant's public comment. Should you have questions 
during the session email [email protected] and someone will respond to your 
message as quickly as possible.
    In order to ensure accuracy, please submit a written copy of oral 
comments for the record by emailing [email protected] by Tuesday, July 20. 
These comments will be shared on the website and reflected in the 
meeting minutes.
    In lieu of oral comments, formal written comments may be submitted 
for the record by Tuesday, July 20 to Helen Lamont, Ph.D., OASPE, 200 
Independence Avenue SW, Room 424E, Washington, DC 20201. Comments may 
also be sent to [email protected]. Those submitting written comments should 
identify themselves and any relevant organizational affiliations.

FOR FURTHER INFORMATION CONTACT: Helen Lamont, 202-260-6075, 
[email protected]. Note: The meeting will be available to the public 
live at www.hhs.gov/live.

SUPPLEMENTARY INFORMATION: Notice of these meetings is given under the 
Federal Advisory Committee Act (5 U.S.C. App. 2, section 10(a)(1) and 
(a)(2)). Topics of the Meeting: Aducanumab, dementia risk reduction, 
recommendations.
    Procedure and Agenda: The meeting will be webcast at www.hhs.gov/live and video recordings will be added to the National Alzheimer's 
Project Act website when available, after the meeting.

    Authority: 42 U.S.C. 11225; Section 2(e)(3) of the National 
Alzheimer's Project Act. The panel is governed by provisions of 
Public

[[Page 34243]]

Law 92-463, as amended (5 U.S.C. Appendix 2), which sets forth 
standards for the formation and use of advisory committees.

    Dated: June 17, 2021.
Rebecca Haffajee,
Acting Assistant Secretary for Planning and Evaluation.
[FR Doc. 2021-13851 Filed 6-28-21; 8:45 am]
BILLING CODE 4150-05-P
```